Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 63
Treatment-assignment count: 0
Stratification count: 0
breast cancer · Monoclonal Antibody
HER2 / ERBB2 expression is flagged as manual review required because public trials show inclusion required evidence in 72 contexts. FDA CDx context exists. Threshold text varies across public records.
Strongest role: Inclusion Required
Inclusion-required count: 63
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 19
Common snippets: HER2-low | HER2-low | HER2-low
Threshold label: Fragmented
CDx label: Fda Cdx Context Exists
CDx maturity score: 5/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT01301729 | https://clinicaltrials.gov/study/NCT01285466 | https://clinicaltrials.gov/study/NCT02536794 | https://clinicaltrials.gov/study/NCT04704661 | https://clinicaltrials.gov/study/NCT00932373 | https://clinicaltrials.gov/study/NCT02226276 | https://clinicaltrials.gov/study/NCT00679211 | https://clinicaltrials.gov/study/NCT00004888 | https://clinicaltrials.gov/study/NCT07657130 | https://clinicaltrials.gov/study/NCT01594177 | https://clinicaltrials.gov/study/NCT01937117 | https://clinicaltrials.gov/study/NCT03321981 | https://clinicaltrials.gov/study/NCT03879577 | https://clinicaltrials.gov/study/NCT07471776 | https://clinicaltrials.gov/study/NCT00493649 | https://clinicaltrials.gov/study/NCT07187752 | https://clinicaltrials.gov/study/NCT00726180 | https://clinicaltrials.gov/study/NCT05795101 | https://clinicaltrials.gov/study/NCT01763710 | https://clinicaltrials.gov/study/NCT04102618 | https://clinicaltrials.gov/study/NCT00436566 | https://clinicaltrials.gov/study/NCT06649331 | https://clinicaltrials.gov/study/NCT07619365 | https://clinicaltrials.gov/study/NCT06886659 | https://clinicaltrials.gov/study/NCT06176261 | https://clinicaltrials.gov/study/NCT05018676 | https://clinicaltrials.gov/study/NCT02491892 | https://clinicaltrials.gov/study/NCT01472146 | https://clinicaltrials.gov/study/NCT01779050 | https://clinicaltrials.gov/study/NCT05919212 | https://clinicaltrials.gov/study/NCT01973660 | https://clinicaltrials.gov/study/NCT02624973 | https://clinicaltrials.gov/study/NCT02752685 | https://clinicaltrials.gov/study/NCT04699630 | https://clinicaltrials.gov/study/NCT00949247 | https://clinicaltrials.gov/study/NCT07195344 | https://clinicaltrials.gov/study/NCT05134519 | https://clinicaltrials.gov/study/NCT00944047 | https://clinicaltrials.gov/study/NCT06533826 | https://clinicaltrials.gov/study/NCT02214004 | https://clinicaltrials.gov/study/NCT07150208 | https://clinicaltrials.gov/study/NCT02571530 | https://clinicaltrials.gov/study/NCT03379428 | https://clinicaltrials.gov/study/NCT01431196 | https://clinicaltrials.gov/study/NCT03304080 | https://clinicaltrials.gov/study/NCT07152782 | https://clinicaltrials.gov/study/NCT04301375 | https://clinicaltrials.gov/study/NCT04578106 | https://clinicaltrials.gov/study/NCT06000033 | https://clinicaltrials.gov/study/NCT05824325 | https://clinicaltrials.gov/study/NCT01832051 | https://clinicaltrials.gov/study/NCT01137994 | https://clinicaltrials.gov/study/NCT05904964 | https://clinicaltrials.gov/study/NCT04674722 | https://clinicaltrials.gov/study/NCT05953168 | https://clinicaltrials.gov/study/NCT03144947 | https://clinicaltrials.gov/study/NCT00320411 | https://clinicaltrials.gov/study/NCT00548184 | https://clinicaltrials.gov/study/NCT04553770 | https://clinicaltrials.gov/study/NCT01534455 | https://clinicaltrials.gov/study/NCT07368543 | https://clinicaltrials.gov/study/NCT00367250 | https://clinicaltrials.gov/study/NCT01306942 | https://clinicaltrials.gov/study/NCT07294430 | https://clinicaltrials.gov/study/NCT02748213 | https://clinicaltrials.gov/study/NCT02776917 | https://clinicaltrials.gov/study/NCT01688609 | https://clinicaltrials.gov/study/NCT00885755 | https://clinicaltrials.gov/study/NCT05081492 | https://clinicaltrials.gov/study/NCT05402722 | https://clinicaltrials.gov/study/NCT02791334 | https://clinicaltrials.gov/study/NCT02996825